Wednesday, December 03, 2025 9:40:40 PM
What a bullshitter. You find stocks after they run.
Then you show a list of info from your software, and you pretend you found the stock early before the move. You fully intend to trick new subscribers to buy your wwaaayyyyy over priced software which you evidence over and over and over that shows you discuss ‘found’ stocks near only after the stock moves higher.
Then you show a list of info from your software, and you pretend you found the stock early before the move. You fully intend to trick new subscribers to buy your wwaaayyyyy over priced software which you evidence over and over and over that shows you discuss ‘found’ stocks near only after the stock moves higher.
© 2025, by StockItOut
Recent KTTA News
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) • GlobeNewswire Inc. • 04/20/2026 11:01:00 AM
- Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity • GlobeNewswire Inc. • 04/01/2026 11:01:00 AM
- Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/17/2026 12:01:00 PM
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines • GlobeNewswire Inc. • 01/13/2026 12:01:00 PM
- Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/02/2025 12:00:00 PM
- Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock • GlobeNewswire Inc. • 11/28/2025 02:20:00 PM
- Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS • GlobeNewswire Inc. • 11/25/2025 12:00:00 PM
- Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data • GlobeNewswire Inc. • 11/24/2025 12:00:00 PM
- Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients • GlobeNewswire Inc. • 11/21/2025 05:35:00 PM
- Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study • GlobeNewswire Inc. • 11/20/2025 09:01:00 PM
- Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 11/04/2025 12:03:00 PM
- Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 09/16/2025 11:03:00 AM
- Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 09/08/2025 11:01:00 AM
- Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/29/2025 12:39:00 PM
- Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/28/2025 11:02:00 AM
- Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 07/31/2025 11:01:00 AM
- Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board • GlobeNewswire Inc. • 06/11/2025 11:02:00 AM
- Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 • GlobeNewswire Inc. • 06/02/2025 12:02:00 PM
- Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases • GlobeNewswire Inc. • 05/20/2025 11:01:00 AM
- Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site • GlobeNewswire Inc. • 05/14/2025 11:02:00 AM
- Pasithea Therapeutics Announces Closing of $5 Million Public Offering • GlobeNewswire Inc. • 05/07/2025 09:00:00 PM
- Pasithea Therapeutics Announces Pricing of $5 Million Public Offering • GlobeNewswire Inc. • 05/06/2025 03:10:00 PM
- Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 • GlobeNewswire Inc. • 05/06/2025 11:03:00 AM
- Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients • GlobeNewswire Inc. • 04/29/2025 11:02:00 AM
